The impact of price controls on rare disease medicines access and lessons for the US
US policy has long recognized this challenge, beginning with the Orphan Drug Act of 1983 and continuing with recent exemptions for certain orphan indications...
This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Kirsten works with leaders in healthcare helping to develop business practices that lead to greater access to affordable medicines, positive public perception, and sustained profitability to support investment in the next generation of innovation.
Kirsten sat on the leadership team of Pfizer Inc’s $30 billion global innovative pharmaceutical business, where she led Strategy and Business Evaluation. Previously, Kirsten led Pfizer’s Global Policy team. She is an Aspen Institute Health Innovator Fellow and a senior advisor to Charles River Associates.
Kirsten recently climbed Mt. Kilimanjaro to raise $1.6 million for cancer research with a team of biotech CEOs and investors.